Revvity, Inc. (RVTY) is a publicly traded company in the Healthcare — Medical - Diagnostics & Research industry listed on NYSE. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide.
Is Revvity, Inc. stock overvalued or undervalued in 2026?
Revvity, Inc. (RVTY) trades at 78.7× earnings (P/E), above the median of the 246 healthcare companies over $2bn in Kaplio's universe. At the decade median (29.6×) $62 (-62 %); at its sector median (30.4×) $64 (-61 %).
Kaplio overview: Revvity, Inc.
Market cap $18B · 52 weeks $82 – $165 (0 % below the high) · P/E 78.7× · 2027 expected P/E 28.1× · Dividend 0.17 % · 4 years rising · Next earnings November 3, 2026 · expected EPS $1.30 · Closing price, Oct 28 · accounts published Aug 4.
- Valuation: P/E 78.7× (expensive).
- Business: ROIC 3 % (weak).
- Balance sheet: Net debt/EBITDA 3.9× (fragile).
- Earnings: 8 of 8 (on track).
What would it be worth at its usual multiples?
At the decade median (29.6×) $62 (-62 %); at its sector median (30.4×) $64 (-61 %). Implied price from applying the reference multiples to today's earnings (or book value, or FFO) per share. Not a fair value: it is where the stock would trade at its usual multiples.
What matters in pharma: 1 of 7 pass
- R&D / Revenue 7.6 %, fails.
- 5y EPS growth −20.0 %, fails.
- Gross margin 53.1 %, fails.
- ROIC 2.9 %, fails.
- Net debt / EBITDA 3.9×, fails.
- P/E vs own 10y history 78.7×, fails.
- FCF / Net Income 210.3 %, passes.
Against its peers (reference peers) — Revvity, Inc.: P/E 78.7×; EV/EBITDA 27.1×; ROIC 2.9 %; $18.4B. Charles River Laboratories International, Inc. (P/E —; EV/EBITDA 94.6×; ROIC 7.7 %; $18.0B), Qiagen N.V. (P/E 25.8×; EV/EBITDA 16.0×; ROIC 8.9 %; $10.4B), Mettler-Toledo International Inc. (P/E 38.2×; EV/EBITDA 27.6×; ROIC 38.2 %; $34.0B).
Expensive or cheap against its last ten years?
P/E at each close: today 78.7× · median 29.6× · minimum 14.8× · maximum 78.7× · cheap below 26.0× · expensive above 41.7×. It has been cheaper than today 100% of the time over its last ten years.
Dividend
solid · Yield 0.17 % ($0.29 per share in 2025) · Years raising it 4 · 5-year growth +1 % a year · Free cash flow coverage 10.6× · With $1,000 invested today you'd collect $1.70 a year ($0.14 a month).
Kaplio's reading: Revvity, Inc.
Updated on October 3, 2026 · accounts published on August 4, 2026
Reading of October 3, 2026: A cash-generative business whose margins, returns and earnings have weakened
Revvity trades at a P/E of 72.2 over the last 12 months, 145 % above its ten-year median of 29.5 and the highest multiple of the past decade.
- Is Revvity expensive or cheap? Revvity's P/E of 72.2 is 164 % above the sector median of 27.4 and the highest it has been in a decade.
- How is the business doing? Operating margin of 12.3 % over the last 12 months trails the 17.2 % average of 2014-2025, and EPS fell 14 %.
- How strong is the balance sheet? Net debt was 3.9× EBITDA in fiscal 2025, above the 2.5× level healthcare treats as healthy, though it equals 16 % of the share price.
- What to expect from the next earnings? Analysts expect EPS of $1.28 when Revvity reports on October 26, 2026, after 8 straight quarters of beating estimates.
- Does Revvity invest enough in R&D and turn profit into cash? Free cash flow was 210 % of net income in fiscal 2025, but R&D at 7.6 % of revenue is half the 15 % healthy mark.
Is Revvity expensive or cheap?
Over the last 12 months Revvity has traded at a P/E of 72.2. That is 145 % above its ten-year median of 29.5 and just below the decade high of 72.8. The median for its 177 healthcare peers is 27.4. EV/EBITDA of 25.1× and P/B of 2.3× look less stretched, but the earnings yield of 1.1 % and the free cash flow yield of 2.3 % are thin. The stock has risen 75 % in a year and is within 1 % of its 52-week high of $152.89, while EPS fell 14 % over the same period. The rally has run well ahead of earnings.
How is the business doing?
Revenue grew 3.7 % over the last 12 months, but EPS fell 13.7 %, so the growth is not reaching the bottom line. The operating margin of 12.3 % is close to fiscal 2025's 12.5 % and well below the 17.2 % average for fiscal 2014-2025. Profitability seems to have settled at a lower level. Returns tell the same story. ROIC is 2.9 % over the last 12 months, 3.4 points below the sector median of 6.3 %. It topped 10 % in only one of the last ten fiscal years, and fiscal 2025 was the weakest at 2.8 %.
How strong is the balance sheet?
Net debt was $23.75 per share in fiscal 2025 ($31.87 of debt against $8.13 of cash), which equals 16 % of today's share price. Against earnings power it looks heavier at 3.9× EBITDA, above the 2.5× that counts as healthy in healthcare. Liquidity is sound, with a current ratio of 1.80 and debt/equity of 0.46 over the last 12 months. A Piotroski score of 7 out of 9 points to solid recent fundamentals, but the Altman Z of 2.5 is in the grey zone. The dividend yields just 0.2 %. It has still risen four fiscal years in a row, with a payout of 14 % in fiscal 2025.
What to expect from the next earnings?
Revvity reports on October 26, 2026, and analysts expect EPS of $1.28 for the quarter. Its track record sets a high bar. It has beaten EPS estimates in each of the last eight quarters. The August 4, 2026 report delivered $1.41 against $1.21 expected, a 17 % surprise and the largest of those eight. Expectations have not moved. The 2026 EPS consensus has held at $5.36 over the last 18 days, and revenue estimates are also steady. Of the 29 analysts covering the stock, 15 rate it a buy, 14 a hold and none a sell.
Does Revvity invest enough in R&D and turn profit into cash?
In healthcare the research pipeline is an asset that does not show on the balance sheet, and expiring patents mean lost revenue. That is why the sector is judged on innovation and cash flow. Revvity is strong on cash: free cash flow was 210 % of net income in fiscal 2025, well above the 90 % considered healthy. It falls short on innovation, with R&D at 7.6 % of revenue against a 15 % benchmark. Gross margin of 53.1 % is below the 70 % typical of branded pharma. EPS shrank 20 % a year over fiscal 2020-2025, against a healthy rate of 8 %.
How this was prepared: the data comes from companies' official filings, collected by a professional provider, and from Kaplio's analysis engine (trailing-12-month ratios, 10 years of history and sector medians computed across US-listed companies). The text is written from that data alone, every figure is checked against it before publication, and it is reviewed when the company reports results. This is not investment advice.
Investor methods verdict
Would Buffett approve Revvity today?
The Buffett Method would not approve Revvity today: it fails its quality rules. Business quality: 65 out of 100 (price not included). Kaplio assessment with data from the week of 2026-10-26; not investment advice.
Would Peter Lynch approve Revvity today?
The Lynch Method approves Revvity today. Business quality: 100 out of 100 (price not included). Lynch classifies it as a turnaround. Kaplio assessment with data from the week of 2026-10-26; not investment advice.
Profitability
| Return on Equity | 3.27% |
| Return on Invested Capital | 2.91% |
| Return on Assets | 1.97% |
| Gross Margin | 52.11% |
| Operating Margin | 12.32% |
| Net Margin | 8.16% |
Financial Health
| Debt / Equity | 0.46 |
| Current Ratio | 1.80 |
| Piotroski F-Score | 7 |
| Altman Z-Score | 2.46 |
Price Performance
| 1 month | +8.22% |
| 3 months | +46.93% |
| Year-to-date | +70.88% |
| 1 year | +73.48% |
| 3 years | +101.43% |
| 5 years | -6.54% |
| 10 years | +224.88% |
Dividend History
Paid in the last 12 months: $0.2800 per share in 4 payments.
| Date | Amount |
|---|---|
| 2026-10-23 | $0.0700 |
| 2026-07-17 | $0.0700 |
| 2026-04-17 | $0.0700 |
| 2026-01-16 | $0.0700 |
| 2025-10-17 | $0.0700 |
| 2025-07-18 | $0.0700 |
| 2025-04-17 | $0.0700 |
| 2025-01-17 | $0.0700 |
| 2024-10-18 | $0.0700 |
| 2024-07-19 | $0.0700 |
Amounts adjusted for stock splits.
Related companies: TECH · TMO · DHR · A · MTD · WAT · CRL · QGEN
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of RVTY: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks